The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications

Bibliography

• ZHANG X, GUREASKO J, SHEN K, COLE PA, KURIYAN J: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 125(6):1137-1149.
   PubMed Web of Science ®Google Scholar
• SCHLESSINGER J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell (2002) 110(6):669-672.
   PubMed Web of Science ®Google Scholar
• OKABAYASHI Y, KIDO Y, OKUTANI T et al.: Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J. Biol. Chem. (1994) 269(28):18674-18678.
   PubMed Web of Science ®Google Scholar
• BOERI ERBA E, BERGATTO E, CABODI S et al.: Systematic analysis of the epidermal growth factor receptor by mass spectrometry reveals stimulation-dependent multisite phosphorylation. Mol. Cell Proteomics (2005) 4(8):1107-1121.
   PubMed Web of Science ®Google Scholar
• GRAUS-PORTA D, BEERLI RR, DALY JM, HYNES NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. (1997) 16(7):1647-1655.
   PubMed Web of Science ®Google Scholar
• GUHA A, GLOWACKA D, CARROLL R et al.: Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome. J. Neurol. Neurosurg. Psychiatry (1995) 58(6):711-714.
   PubMed Web of Science ®Google Scholar
• GUHA A, DASHNER K, BLACK PM, WAGNER JA, STILES CD: Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer (1995) 60(2):168-173.
   PubMed Web of Science ®Google Scholar
• GUHA A, FELDKAMP MM, LAU N, BOSS G, PAWSON A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene (1997) 15(23):2755-2765.
   PubMed Web of Science ®Google Scholar
• OLSON MF, MARAIS R: Ras protein signalling. Semin. Immunol. (2000) 12(1):63-73.
   PubMed Web of Science ®Google Scholar
• ALESSI DR, ANDJELKOVIC M, CAUDWELL B et al.: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. (1996) 15(23):6541-6551.
   PubMed Web of Science ®Google Scholar
• TOKER A, YOELI-LERNER M: Akt signaling and cancer: surviving but not moving on. Cancer Res. (2006) 66(8):3963-3966.
   PubMed Web of Science ®Google Scholar
• SARBASSOV DD, GUERTIN DA, ALI SM, SABATINI DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307(5712):1098-1101.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI A, ZHAI G, SUZUKI Y et al.: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. (2004) 22(10):1926-1933.
   PubMed Web of Science ®Google Scholar
• CHOE G, HORVATH S, CLOUGHESY TF et al.: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. (2003) 63(11):2742-2746.
   PubMed Web of Science ®Google Scholar
• DENNIS PB, JAESCHKE A, SAITOH M et al.: Mammalian TOR: a homeostatic ATP sensor. Science (2001) 294(5544):1102-1105.
   PubMed Web of Science ®Google Scholar
• FINGAR DC, RICHARDSON CJ, TEE AR et al.: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. (2004) 24(1):200-216.
   PubMed Web of Science ®Google Scholar
• FINGAR DC, SALAMA S, TSOU C, HARLOW E, BLENIS J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. (2002) 16(12):1472-1487.
   PubMed Web of Science ®Google Scholar
• GINGRAS AC, RAUGHT B, SONENBERG N: Regulation of translation initiation by FRAP/mTOR. Genes Dev. (2001) 15(7):807-826.
   PubMed Web of Science ®Google Scholar
• BURNETT PE, BARROW RK, COHEN NA, SNYDER SH, SABATINI DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA (1998) 95(4):1432-1437.
   PubMed Web of Science ®Google Scholar
• SARBASSOV DD, ALI SM, KIM DH et al.: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. (2004) 14(14):1296-1302.
   PubMed Web of Science ®Google Scholar
• KIM DH, SABATINI DM: Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr. Top. Microbiol. Immunol. (2004) 279:259-270.
   PubMed Web of Science ®Google Scholar
• KIM DH, SARBASSOV DD, ALI SM et al.: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 110(2):163-175.
   PubMed Web of Science ®Google Scholar
• AOKI M, BLAZEK E, VOGT PK: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA (2001) 98(1):136-141.
   PubMed Web of Science ®Google Scholar
• PODSYPANINA K, LEE RT, POLITIS C et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA (2001) 98(18):10320-10325.
   PubMed Web of Science ®Google Scholar
• VEGA F, MEDEIROS LJ, LEVENTAKI V et al.: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. (2006) 66(13):6589-6597.
   PubMed Web of Science ®Google Scholar
• RIEMENSCHNEIDER MJ, BETENSKY RA, PASEDAG SM, LOUIS DN: AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. (2006) 66(11):5618-5623.
   PubMed Web of Science ®Google Scholar
• CONDE E, ANGULO B, TANG M et al.: Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin. Cancer Res. (2006) 12(3 Pt. 1):710-717.
   PubMed Web of Science ®Google Scholar
• EKSTRAND AJ, SUGAWA N, JAMES CD, COLLINS VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA (1992) 89(10):4309-4313.
   PubMed Web of Science ®Google Scholar
• SUGAWA N, EKSTRAND AJ, JAMES CD, COLLINS VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA (1990) 87(21):8602-8606.
   PubMed Web of Science ®Google Scholar
• MOSCATELLO DK, HOLGADO-MADRUGA M, GODWIN AK et al.: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. (1995) 55(23):5536-5539.
   PubMed Web of Science ®Google Scholar
• WONG AJ, RUPPERT JM, BIGNER SH et al.: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA (1992) 89(7):2965-2969.
   PubMed Web of Science ®Google Scholar
• HUANG HS, NAGANE M, KLINGBEIL CK et al.: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. (1997) 272(5):2927-2935.
   PubMed Web of Science ®Google Scholar
• MOSCATELLO DK, MONTGOMERY RB, SUNDARESHAN P et al.: Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene (1996) 13(1):85-96.
   PubMed Web of Science ®Google Scholar
• FERNANDES H, COHEN S, BISHAYEE S: Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J. Biol. Chem. (2001) 276(7):5375-5383.
   PubMed Web of Science ®Google Scholar
• LAL A, GLAZER CA, MARTINSON HM et al.: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. (2002) 62(12):3335-3339.
   PubMed Web of Science ®Google Scholar
• PANDITA A, ALDAPE KD, ZADEH G, GUHA A, JAMES CD: Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 39(1):29-36.
   PubMed Web of Science ®Google Scholar
• BIGNER SH, HUMPHREY PA, WONG AJ et al.: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. (1990) 50(24):8017-8022.
   PubMed Web of Science ®Google Scholar
• GIANNINI C, SARKARIA JN, SAITO A et al.: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol. (2005) 7(2):164-176.
   PubMed Web of Science ®Google Scholar
• LUND-JOHANSEN M, BJERKVIG R, HUMPHREY PA et al.: Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res. (1990) 50(18):6039-6044.
   PubMed Web of Science ®Google Scholar
• PARK CM, PARK MJ, KWAK HJ et al.: Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. (2006) 66(17):8511-8519.
   PubMed Web of Science ®Google Scholar
• SONODA Y, OZAWA T, HIROSE Y et al.: Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. (2001) 61(13):4956-4960.
   PubMed Web of Science ®Google Scholar
• HOLLAND EC, HIVELY WP, DEPINHO RA, VARMUS HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. (1998) 12(23):3675-3685.
   PubMed Web of Science ®Google Scholar
• WEI Q, CLARKE L, SCHEIDENHELM DK et al.: High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res. (2006) 66(15):7429-7437.
   PubMed Web of Science ®Google Scholar
• BENHAR M, ENGELBERG D, LEVITZKI A: Cisplatin-induced activation of the EGF receptor. Oncogene (2002) 21(57):8723-8731.
   PubMed Web of Science ®Google Scholar
• CONTESSA JN, HAMPTON J, LAMMERING G et al.: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene (2002) 21(25):4032-4041.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ULLRICH RK, MIKKELSEN RB, DENT P et al.: Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene (1997) 15(10):1191-1197.
   PubMed Web of Science ®Google Scholar
• LAMMERING G, VALERIE K, LIN PS et al.: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer Res. (2001) 7(3):682-690.
   PubMed Web of Science ®Google Scholar
• LEARN CA, HARTZELL TL, WIKSTRAND CJ et al.: Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin. Cancer Res. (2004) 10(9):3216-3224.
   PubMed Web of Science ®Google Scholar
• AHN NG, RESING KA: Cell biology. Lessons in rational drug design for protein kinases. Science (2005) 308(5726):1266-1267.
   PubMed Web of Science ®Google Scholar
• SANDSTROM M, JOHANSSON M, ANDERSSON U et al.: The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br. J. Cancer (2004) 91(6):1174-1180.
   PubMed Web of Science ®Google Scholar
• NAKATA E, HUNTER N, MASON K et al.: C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(4):1163-1173.
   PubMed Web of Science ®Google Scholar
• NASU S, ANG KK, FAN Z, MILAS L: C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. (2001) 51(2):474-477.
   PubMed Web of Science ®Google Scholar
• WU G, BARTH RF, YANG W et al.: Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. (2006) 5(1):52-59.
   PubMed Web of Science ®Google Scholar
• MAMOT C, DRUMMOND DC, NOBLE CO et al.: Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. (2005) 65(24):11631-11638.
   PubMed Web of Science ®Google Scholar
• RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. (2004) 22(1):133-142.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI A, BERKEY B, ROBINS HI et al.: An update of Phase II results from RTOG 0211: a Phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. 2006 ASCO Annual Meeting. 20 June 2006, Atlanta, GA, USA (2006).
   Google Scholar
• PRADOS MD, LAMBORN KR, CHANG S et al.: Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol. (2006) 8(1):67-78.
   PubMed Web of Science ®Google Scholar
• SADONES J, CHASKIS C, JOOSENS EJ et al.: A stratified Phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. 2006 ASCO Annual Meeting. 20 June 2006, Atlanta, GA, USA (2006).
   Google Scholar
• COMBS SE, HEEGER S, HASELMANN R et al.: Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-Phase I/II trial: study protocol. BMC Cancer (2006) 6:133.
   PubMed Web of Science ®Google Scholar
• LASSMAN AB, ROSSI MR, RAIZER JJ et al.: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. (2005) 11(21):7841-7850.
   PubMed Web of Science ®Google Scholar
• HAAS-KOGAN DA, PRADOS MD, TIHAN T et al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. (2005) 97(12):880-887.
   PubMed Web of Science ®Google Scholar
• PARRA HS, CAVINA R, LATTERI F et al.: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer. Br. J. Cancer (2004) 91(2):208-212.
   PubMed Web of Science ®Google Scholar
• MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353(19):2012-2024.
   PubMed Web of Science ®Google Scholar
• FAN QW, KNIGHT ZA, GOLDENBERG DD et al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 9(5):341-349.
   PubMed Web of Science ®Google Scholar
• CHANG SM, WEN P, CLOUGHESY T et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs (2005) 23(4):357-361.
   PubMed Web of Science ®Google Scholar
• REARDON DA, QUINN JA, VREDENBURGH JJ et al.: Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. (2006) 12(3 Pt. 1):860-868.
   PubMed Web of Science ®Google Scholar
• DOHERTY L, GIGAS DC, KESARI S et al.: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology (2006) 67(1):156-158.
   PubMed Web of Science ®Google Scholar
• LI B, CHANG CM, YUAN M, MCKENNA WG, SHU HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. (2003) 63(21):7443-7450.
   PubMed Web of Science ®Google Scholar
• FAN QW, SPECHT KM, ZHANG C et al.: Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res. (2003) 63(24):8930-8938.
   PubMed Web of Science ®Google Scholar